These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26669072)

  • 1. [Hyperphosphatemia in Chronic Kidney Disease (CKD)].
    Wang J; Zhang XY; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2015 Aug; 46(4):241-4. PubMed ID: 26669072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of the skeleton and phosphorus in the CKD mineral bone disorder.
    Hruska KA; Mathew S
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):98-104. PubMed ID: 21406294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease.
    Tani T; Orimo H; Shimizu A; Tsuruoka S
    Sci Rep; 2017 May; 7(1):2233. PubMed ID: 28533541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of phosphorus load in CKD patients.
    Taketani Y; Koiwa F; Yokoyama K
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
    Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
    Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease.
    Winiarska A; Filipska I; Knysak M; Stompór T
    Nutrients; 2021 Feb; 13(3):. PubMed ID: 33673618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.
    Zhou C; Wang F; Wang JW; Zhang LX; Zhao MH
    Chin Med J (Engl); 2016 Oct; 129(19):2275-80. PubMed ID: 27647184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Dietary Phosphorous Restriction on Fibroblast Growth 2 Factor-23 and sKlotho Levels in Patients with Stages 1-2 Chronic Kidney Disease.
    Saxena A; Sachan T; Gupta A; Kapoor V
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin and Chronic Kidney Disease.
    Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
    Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
    Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast Growth Factor-23 Concentration in Dogs with Chronic Kidney Disease.
    Harjes LM; Parker VJ; Dembek K; Young GS; Giovaninni LH; Kogika MM; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):784-790. PubMed ID: 28419560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease.
    Mathew S; Davies M; Lund R; Saab G; Hruska KA
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():43-50. PubMed ID: 16884397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of phosphorus in the pathophysiology of chronic kidney disease.
    Geddes RF; Finch NC; Syme HM; Elliott J
    J Vet Emerg Crit Care (San Antonio); 2013; 23(2):122-33. PubMed ID: 23464730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.
    Tsuboi Y; Ohtomo S; Ichida Y; Hagita H; Ozawa K; Iida M; Nagao S; Ikegami H; Takahashi T; Horiba N
    Kidney Int; 2020 Aug; 98(2):343-354. PubMed ID: 32624180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.